With respect to liver manifestation, emerging RNAi-based therapeutics targeting hepatic Z-AAT production currently in development may, if proven to be safe and efficacious, benefit patients with AATD-associated liver disease in the future33,34. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.